The war on cancer: An anatomy of failure, a blueprint for the future

The War on Cancer: An Anatomy of Failure, A Blueprint for the Future

Volumn , Issue , 2005, Pages 1-227

  Faguet, Guy B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900894218     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-3617-0     Document Type: Book

References (450)

1. Ries LAG, Kosary CL, Hankey BF, et al. Editors. SEER Cancer Statistic Review, 1973-199. Bethesda, MD: National Cancer Institute, 1999.
2. National Heart, Lung, and Blood Institute. Fact Book Fiscal Year 2002. www.nhlbi.nih.gov/about/02factbk.pdf.
3. McGeary M, Burstein M. Sources of cancer research funding in the United States. Prepared for National Cancer Policy Board, Institute of Medicine. June, 1999.
4. Jemal A, Tiwari RC, Murray T, et al. Cancer Facts & Figures 2004. CA Cancer J Clin 2004;54:8-29. http://www.cancer.org/docroot/STT/stt-0.asp
5. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2000, Natl Cancer Inst. Bethesda, MD, http://seer.cancer.gov/csr/1975-2000/ .pdf
6. Resident population estimates of the United States by Age and Sex: April 1, 1990 to July 1, 1999, with short-term projection to November 1, 2000 U. S. Bureau of the Census, Washington, D. C. 20233, http://www.census.gov/population/ estimates/nation/intfile2-1.txt
7. Percy CL, Miller BA, Ries LAG. Effect of changes in cancer classification and the accuracy of death certificates on trends in cancer mortality. Ann NY Acad Sci 609:87-97, 1990.
8. Swan J, Wingo P, Clive R, et al. Cancer surveillance in the United States: Can we have a national system? Cancer 83:1282-1291, 1998.
9. Surveillance, Epidemiology, and End Results. About SEER http://seer.cancer.gov/about
10. SEER Program (www.cancer.gov) SERR*Stat Dataase: Incidence - SEER 9 Regs Public-Use, Nov. 2002 Sub (1973-2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission.
11. Landis SH, Murray T, Bolden S, et al. Cancer Statistics, 1999. CA Cancer J Clin 49:8-31, 1999.
12. e.5, 2000. http://www.cancer.gov/downloads/PUB/DOCS/ SECTION4/23pdf
13. Estimated US Cancer Prevalence. http://cancercontrol.cancer.gov/ocs/ prevalence/prevalence.html urvivor
14. Devesa FS, Silverman DT, Young JL, et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Nat Cancer Inst 79:701-770, 1987.
15. Nomura A. Stomach cancer. In: Cancer epidemiology and prevention, 2nd ed. Schottenfeld D, Fraumeni JF, editor. New York; Oxford University Press; 1996 p707-724.
16. Gann PH. Interpreting recent trends in prostate cancer incidence and mortality. Epidemiology 8:117-119, 1997.
17. Welch HG, Schwartz LM, and Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? J Am Med Assoc 283:2975-2978, 2000.
18. Black WC and Welch HG. Advances in diagnostic imaging and overestimation of disease prevalence and the benefits of therapy. N Engl J Med 328:1237-1243, 1993.
19. 2001 Cancer Progress Report, http://progressreport.cancer.gov
20. Arias E, Anderson RN, Hsiang-Ching K, et al. Deaths: Final data for 2001. National vital statistics reports: vol. 52 no 3. Hyattsville, MD: National Center for Health Statistics. 2003. http://www.cdc.gov/nchs/data/nvsr/nvsr52/ nvsr52-03.html.
21. Centers for Disease Control and Prevention. National Center for Health Statistics, http://ea.grolier.com/eaonline/wsja/text/ch08/tables/lv/27.htm
22. National population projections III Population pyramids 1990-2100, http://www.census.gov/population/www.projections/natchart.html
23. Jemal A, Thomas A, Murray T, et al. Cancer Statistics, 2002 CA Cancer Clin 52:23-47, 2002. http://www.cancer.org/downloads/STT/ CancerFact&Figures2002TM.p df
24. US Cancer Statistics Working Group. United States Cancer Statistics: 2000 Incidence. Atlanta (GA): department of Health and Human Services, Center for Disease Control and Prevention and National Cancer Institute; 2003.
25. SEER Cancer statistics Review 1973-1997 Table I-3, Summary of changes in cancer incidence and mortality, 1950-1997 and 5-year relative survival rates, 1950-1996.
26. SEER Cancer statistics Review 1973-1998, Table I-2 (49-year trends in US cancer mortality rates).
27. Kardinal CG, Yabro JW. A conceptual history of cancer. Sem Oncol 6:396-408, 1979.
28. Hippocrates, Aphorism #38 Book 6
29. Celsus AC. De Medicina, book 5, Chapter 8.
30. Aetius of Amida, Book 14, chapter 4. Edited by Janus Cornarius, Venice 1534
31. Galen C. On tumors beyond nature, Chapter 13.
32. Wolf J. The Science of cancerous diseases from earliest times to the present. Science History Publications USA, 1989 pg12.
33. Andreae Vesalii Bruxellensis, scholae medicorum Patavinae professoris, De humani corporis fabrica libri septem. Basilae: Joannis Oporini (printer), Mense Junio, 1543.
34. Ambroise Paré, (a brief biography) http://ambroise.pare.free.fr
35. Paré A. In Hamby WB. The Case Reports and Autopsy Records of Ambroise Paré. Springfield, IL: C. C. Thomas; 1960 [As cited in Shimkin MB, Contrary to Nature: Cancer, p. 57 (q.v.)].
36. Cited by Wolff Jacob, in The Science of cancerous disease from earliest times to the present. Science History Publications, 1989, p42
37. Descartes R. Discours de la méhode pour bien conduire sa raison et chercher la vérité dans les sciences, 4e partie, 2e Méditation.
38. Aselli G, De lactibus sive Lacteis venis, 1627
39. Bett WR: Historical aspects of cancer, in Raven RR (ed) Cancer, vol I. Butterworth, London 1957, pp 1-5.
40. Petit J-L. Oeuvres completes, Limopes 1837, pg 438
41. (cited in Wolf J. The Science of cancerous diseases from earliest times to the present. Science History Publications USA 1989, pg 50.
42. Petit J-L. Essai sur le cancer des mammelles, cited by Darmon P, in Les céllules folles, Plon, Paris 1993.
43. Peyrhile B. Dissertatio academica de cancro, Lyon, 1773
44. (cited in Wolf J. The Science of cancerous diseases from earliest times to the present. Science History Publications USA 1989, pp 54-55).
45. Ramazzini B. De Moribus Artificum Diatriba. 1713.
46. [Translation by Wright WC reprinted in Birmingham, AL: Classics of Medicine Library; 1983
47. Griffiths, M. Nuns, virgins, and spinsters: Rigoni-Stern and cervical cancer revisited. British Journal of Obstetrics and Gynecology. 98:797-802, 1991.
48. Hill J. Cautions against the immoderate use of snuff and the effects it must produce when this way taken into the body. London: R. Baldwin & J. Jackson
49. Bayle GL et Cayole. Cancer, in Dictionnaire des sciences médicales, Pankouke, Paris, 1812, vol III, p 671.
50. Broca PP. Mémoire sur l'anatomie pathologique du cancer. Bulletin de la Société anatomique de Paris, 1850, 25:45 et seq.
51. Virchow R. Die Cellular pathologie, 1858.
52. Velpeau AALM. Traité des maladies du sein, Paris 1853.
53. Remak R, described in Muler's Archiv, 1852, p 57
54. as quote in Wolf J. The Science of cancerous diseases from earliest times to the present. Science History Publications USA, 1989, p182.
55. Bard L. Anatomie générale des tumeurs, Lyon 1895.
56. Boveri T, Zur Frage der Entstehung maligner tumorem, 1914.
57. Holmes OW. Currents and countercurrents in medical science, with other addresses and essays (Boston: Ticknor and Fields, 1861), p. 39.
58. cited in Parascandola J. From germs to Genes: Trends in drug therapy, 1852-2002. Pharm Hist 44(1):3-11, 2002
59. Peller, S. Cancer research since 1900. An evaluation. Philosophical Library, New York, 1979.
60. Fibiger JAG, The Nobel Prize in Physiology or Medicine 1926, http://www.nobel.se/medicine/laureates/1926/index.html
61. Asghar RJ, Parsonnet J. Helicobacter pylori and risk for gastric adenocarcinoma. Semin Gastrointest Dis 12(3):203-8, 2001
62. Seto M. Genetic and epigenetic factors involved in B-cell lymphomas. Cancer Sci 95:704-710, 2004
63. Long CW. An account of the first use of sulphuric ether. Southern Med & Surg J 5:705-713, 1849.
64. Lister J. On the antiseptic principle in the practice of surgery. The Lancet, 90:353-356, 1867.
65. Asimov I. Asimov's biographical encyclopedia od science and technology.: The living stores of more than 1, 000 great scientists from the Age of Greece to the Space Age, chronologically arranged. Garden City, NJ. Doubleday.
66. Flores J. Específico nuevamente descubierto en el reyno de Goatemala para la curacion the horrible mal de cancro y otros mas frecuentes, Cadiz, 1783.
67. Maunoir CT. Nouvelle méthode pour traiter le sarcocele sans extirper le testicule. Genève, 1820.
68. Boehm-Viswanathan T. Is angiogenesis inhibition the Holy Grail of cancer therapy? Curr Opin Oncol 12:89-94, 2000.
69. Bennett H. On cancerous and cancroid growths, Edinburgh, 1849, p237.
70. Arnot J. Practical observations of the remedial efficacy of anaesthesic temperature in cancer, Lancet, Volume II, p257, 1850
71. Zaffaroni N, Fiorentini G, De Giorgi U. Hyperthermia and hyposia: New developmentsin anticancer chemotherapy. Eur J Surg Oncol 27:340-342, 2001.
72. Greve JW. Alternative techniques for the treatment of colon carcinoma metastases in the liver: current status in The Netherlands. Scand J Gastroenterol Suppl 234:77-81, 2001.
73. Mala T, Edwin B, Gladhaug I, et al. Magnetic-resonance-guided percutaneous cryoablation of hepatic tumors. Eur J Surg 167:610-617, 2001.
74. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
75. Harris NL, Jaffe ES, Kiebold J, et al. Lymphoma classification-from controversy to consensus: the REAL and WHO Classification of lymphoid neoplasms. Ann Oncol 11(suppl 1):S3-S10, 2000.
76. Faguet GB. Chronic lymphocytic leukemia: An updated review. J Clin Oncol 12:1974-1990, 1994.
77. Chronic lymphocytic leukemia: Advances in Molecular biology, Cytogenetics, Diagnosis, and Management. Ed Guy B. Faguet, Humana Press, 2003.
78. Age-adjusted incidence and U. S. deaths rates and 5-year relative survival rates (Table I-4), http://seer.cancer.gov/csr/1973-1999/overview/ overview1.pdf
79. Venter JC, Adams MD, Meyers EW, et al. The sequence of the human genome. Science 291:1304-1351, 2001.
80. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409:860-921, 2001.
81. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073-80, 1989
82. M. H. Polymeropoulos, C. Lavedan, E. Leroy, S. E. et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease. Science 276:2045-2047, 1997.
83. Watson James. The double Helix: A personal account of the discovery of the structure of DNA. Simon & Schuster; ISBN: 0684852799 1998. (1998)
84. Parshall G, Licking EF, James D, Watson JD, Francis Crick: Double-Teaming the Double Helix. US News & World Report, August 17, 1998, http:\\www.usnews.com/usnews/issue/980817/17dna.htm
85. Watson J, Crick F. A structure for deoxyribose nucleic acid. Nature 171:737, 1953.
86. Sayre Anne. Rosalind Franklin and DNA. W. W. Norton & Company; ISBN: 0393320448 (2000)
87. http://www.ornl.gov/hgmis/posters/chromosome
88. Sandberg A, Chen Z. Cytogenetic Analysis, in Hematologic Malignancies: Methods and Techniques, Ed Guy B Faguet, Human Press Inc., Totowa, New Jersey, 2001
89. Stadberg A, Chen Z. FISH analysis. in Hematologic Malignancies: Methods and Techniques, Ed Guy B Faguet, Human Press Inc., Totowa, New Jersey, 2001
90. Baudis M, Bentz M. Comparative genomic hybridization, in Hematologic Malignancies: Methods and Techniques, Ed Guy B Faguet, Human Press Inc., Totowa, New Jersey, 2001
91. Higenfeld E, Padilla-Nash H, Haas OA, et al. Spectral karyotyping (SKY) of hematologic malignancies, in Hematologic Malignancies: Methods and Techniques, Ed Guy B Faguet, Human Press Inc., Totowa, New Jersey, 2001
92. Mohr S, Leikauf GD, Keith G, et al. Microarrays as cancer keys: An array of possibilities. J Clin Oncol 20:3165-3175, 2002.
93. Tsujimoto, Y., Gorham, J., Cossman, J., et al. The t (14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science, 229:1390-1393, 1985.
94. Moyzis RK, Buckingham JM, Cram LS, et al. A highly conserved repetitive DNA sequence (TTAGGG) present at the telomeres oh human chromosomes. Proc Natl Acad Sci USA 85:6622-6626, 1988.
95. Shay JW and Bachetti S. A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791, 1997.
96. Futreal PA, Kspryk A, Birney E, et al. Cancer and Genomics. Nature 409:850-855, 2001.
97. Hamblin TJ. Heterogeneous origin of the B-CLL cell, in Chronic Lymphocytic Leukemia: Advances in Molecular genetics, Biology, Diagnosis, and Management. Ed Guy B Faguet. The Humana Press, 2003.
98. Pignatelli M. Integrins, cadherins, and catenins: molecular cross-talk in cancer cells. J Pathol 186:1-21, 1998.
99. Fidler I, Molecular biology of cancer: invasion and metastases. In: V. T. De Vita, S. Hellman, and S. A. Rosenberg (eds), Cancer principles and practice of oncology, Ed. 5, pp 135-152, New York: Lippincott-Raven, 1997.
100. Cronin K, Feuer E, Wesley M, et al. Current estimates for 5 and 10 year relative survival. Statistical Research and Applications Branch, NCI, Technical Report #2003-04.
101. Yoshida BA, Mitchell M, Sokoloff D, et al. Metastasis-suppressor genes: A review and perspective on an emerging field. Oncol Spectrums 2:166-192, 2001.
102. Heimann R, Lan F, McBride R, et al. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-adherin. Nature 283:139-146, 1980.
103. Heimann R, Ferguson DJ and Hellman S. The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer. Cancer Res 58:2766-2771, 1998.
104. Arber E. Cell proliferation as a major risk for cancer: a concept of doubtful validity. Cancer Res 55:3759-3762, 1995.
105. Rosenberg SA. Identification of cancer antigens: impact on development of cancer immunotherapies. Cancer J Sci Am 6(Suppl 3):S200-207, 2000
106. Reddy A, Kaelin G Jr. Using cancer genetics to guide the selection of anticancer drug targets. Curr Op Pharmacol 2:366-373, 2002.
107. De Vita VT Jr, Serpick A. A combination chemotherapy in the treatment of Hodgkin's disease (HD). Proc Am Assoc Cancer Res 8:13, 1967 (abstract).
108. Burnett FM. The concept of immunological surveillance, Prog Exp Tumor 13:1-27, 1970.
109. Immune Surveillance. Eds RT Smith and M Landry. Academic Press, New York - London, 1970.
110. Mathé G, Amiel JL, Schwarzenberg L, et al. Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1:697-699, 1969.
111. Grasser I. Interferon and cancer: therapeutic prospects. Rev Eur Etud Clin Biol 15:23-7, 1970.
112. Amery WK, Spreafico F, Rojas AF, et al. Adjuvant treatment with levamisole in cancer: a review of experimental and clinical data. Cancer Treat Rev 4:167-94, 1977
113. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985.
114. Nelkin, D. Selling Science: how the press covers science and technology, W. H. Freeman & Company, New York, 1995.
115. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 411:380-384, 2001.
116. Jager E, Knuth A. Clinical cancer vaccine trials. Current opinion in immunology 14:178-182, 2002.
117. Blattner W. Epidemiology of HTLV-1 and associated diseases. (Blattner W, ed.). In Human retrovirology: HTLV-1. New York: Raven Press, 1990, 251-265.
118. Gallo RC, Montagnier L. The chronology of AIDS research. Nature. 326:435-6, 1987
119. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS related body-cavity-based lymphomas. N Engl J Med 332:1186-1191, 1995.
120. Einstein MH, Goldberg GL. Human papillovirus and cervical neoplasia. Cancer Invest 20:1080-1085, 2002.
121. Blumberg BS, London WT. Hepatitis B virus: Pathogenesis and prevention of primary cancer of the liver. Cancer 50:2657-2665, 1982.
122. Simonetti RG Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann Int Med 116:97-102, 1992.
123. Litter E, Baylis SA, Zeng Y, et al. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. Lancet 337:685-689, 1991.
124. Hematologic Malignancies: Methods and techniques. GB Faguet editor. Humana Press, 2001.
125. Brisco MJ. Quantifying residual leukemia by "clone-specific" polymerase chain reaction, in Hematologic Malignancies: Methods and techniques, GB Faguet editor, Humana Press, 2001.
126. Outcomes Working Group, Health Services Research Committee, America Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679, 1996
127. Encyclopedia of the First World War: Deaths from gas attacks, http://www.spartacus.schoolnet.co.uk/FWWgasdeaths.htm
128. Kumbhaar EB, Kumbhaar HD. The blood and bone marrow in Yellow Cross Gas (Mustard Gas) poisoning: Changes produced in the bone marrow of fatal cases. J Med Res 40:497-507, 1919.
129. Pappenheimer AM, Vance M. The effects of intravenous injections of Di-Chloroethylsulfide in rabbits, with special reference to its leukotoxic action. J Exp Med 31:71-95, 1920.
130. Berenblum I. Experimental inhibition of tumor induction by mustard gas and other compounds. J Path Bact 40:549-558, 1935.
131. Einhorn J. Nitrogen mustard: The origin oc chemotherapy for cancer. Int J Radiation Oncologt Biol Phys 11:1375-1378, 1985.
132. Goodman LS, Wintrobe MM, Dameshek W, et al. Use of methyl-bis-(β- chloroethyl) amine hydrochloride and tris-(β-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. JAMA 132:126-132, 1946.
133. Alexander SF. Medical report of the Bari Harbor Mustard casualties. The Military Surgeon 10:2-17, 1947.
134. Jacobson LO, Spurr CL, Barron ES, et al. Studies of the effect of methyl methyl-bis-(β-chloroethyl) amine hydrochloride on neoplastic diseases and allied disorders of the hemopoietic system. JAMA 132:263, 1946.
135. Karnofsky DA, Carver LF, Rhoads CF et al. An evaluation of methylbis-(β-chloroethyl) amine hydrochloride (nitrogen mustards) in the treatment of lymphomas, leukemias, and allied diseases, in Moulton FR (ed): Approach to cancer chemotherapy. Washington DC, AAAS, 1947.
136. Rhoads CP. Report on a cooperative study of nitrogen mustard (HN2) therapy of neoplastic disease. Trans Assoc Am Physicians 60, 1947.
137. Goodman LS, Wintrobe MM, Dameshek W, et al. Nitrogen mustard therapy. JAMA 132:126-132, 1946.
138. Woods DD. The relation of p-aminobenzoic acid to the mechanism of action of sulfaniamide. Br J Exp Pathol 21:74, 1940.
139. Fildes P. A rational approach to research in chemotherapy. Lancet 1:995, 1940.
140. Seeger DR, Smith JM Fr, Hultquist ME. Antigonist for pteroylglutamic acid. J Am Chem Soc 69:2567, 1947.
141. Seeger DR, Cosulich DB, Smith JM Jr, et al. Analogs of pteroylglutamic acid III. 4-amino derivatives. J Am Chem Soc 71:1753, 1949.
142. Farber S, Diamond LK, Mercer RD et al. Temporary remissions in acute leukemia in children produced by the folic acid antigonist, 4- aminopteroylglutamic acid (Aminopterin). N Engl J Med 238:787, 1948.
143. Hertz R, Lewis J, Lipsett M. Five years experience with chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women. Am J Obstet Gynecol 1961;82:631.59.
144. Burchenal JH, Murphy ML, Ellison RR, et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 8:965, 1953.
145. Murphy ML, Tan TC, Ellison RR, et al. Clinical evaluation of chloroquine and thioguanine. Proc Am Assoc Cancer Res 2:36, 1955 (abstract).
146. th, 2001, p53.
147. Drug discovery at the National Institute of Cancer, March 1, 2002, http://newscenter.cancer.gov/pressreleases/discovery.html
148. Bainbridge WS. The cancer problem. New York, MacMillan, 1914.
149. Sikora K, Advani S, Koroltchouk V, et al. Essential drugs for cancer therapy: A World Health Organization Consultation. Annals Oncol 10:385-390, 1999 (revised list posted in April 2003 http://mednet3.int/Eml/disease-factsheet. asp?diseaseId=530).
150. Woglom WH. General review of cancer therapy, in Moulton FR (ed): Approaches to tumor chemotherapy. Washington, DC AAAS, 1947, pg1.
151. Druker BJ, Talpaz M, Resta DJ, et al, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001.
152. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 62:1117-1133, 1978.
153. Skipper HE. Historic milestones in cancer biology: a few that are important to cancer treatment (revisited). Semin Oncol 6:506-514, 1979.
154. Mendelsohn ML. The growth fraction: a new concept applied to tumors. Science 132:1496, 1960.
155. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutations rate. Cancer Treat Rep 63:1727-1733, 1979.
156. Laird AK. Dynamics of growth in tumors and normal organisms, Natl Cancer Inst Monogr 30:15-281969.
157. Bonadonna G, Rossi A, Valagussa BS. Adjuvant CMF in operable breast cancer: ten years later. Wolrd J Surg 5:95-115, 1985.
158. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002.
159. Breathnach O, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19:1734-1742, 2000.
160. Karnofsky DA, Abelmann WH, Craver LF, et al. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 634-656, 1948.
161. Kennedy BJ. The snail's pace of lung carcinoma chemotherapy. Cancer 82:801-803, 1998.
162. Non-small cell lung cancer collaborative group. Chemotherapy for nonsmall cell lung cancer (Cochrane Review), In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
163. Schiller J, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-8, 2002.
164. Evans WK. The cost and cost-effectiveness of treating non-small cell lung cancer. Oncology Spectrums 3:35-41, 2002.
165. Martin DS, Gelhorn A. Combinations of chemical compounds in experimental cancer chemotherapy. Cancer Res 11:35, 1951.
166. Skipper HE. Nucleotide metabolism and cancer chemotherapy, in Rebuck JW, Bethell FH, Monto RW (eds): The Leukemias: Etiology, Pathophysiology, and Treatment. New York, Academic 1957, p541.
167. Freireich EJ, Karon M, Frei E III. Quadruple combination therapy (VAMP) for acute lymphoblastic leukemia of childhood. Proc Am Assoc Cancer Res 5:20, 1964 (abstract).
168. De Vita VT Jr, Serpick A. Combination chemotherapy in the treatment of advanced Hodgkin's disease (HD). Proc Am Assoc Cancer Res 8:13, 1967 (Abstract)
169. Devita VT Jr, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy: Long-term followu-up of MOPP-treated patients at the National Cancer Institute (NCI). Ann Intern Med. 92:586-595, 1980.
170. Donohue JP, Einhorn LH, Perez JM. Improved management of nonseminomatous testis tumors. Cancer 42:2903-8, 1978.
171. Surbone A and De Vita VT Jr. Dose intensity. The neglected variable in clinical trials. Ann NY Acad Sci 698:279-288, 1993.
172. Hryaiuk WA, Figueredo A, Goodyear M. Application of dose intensity to problems in chemotherapy of breast and colon cancer. Semin Oncol 1987;14 (suppl 4) 3-11.
173. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. The Oncologist 6:3-10, 2001.
174. Aublanc JB. Dissertations sur le cancer. Paris 1803, pg 40.
175. Stephenson J. Bone marrow/Stem cells: No edge in breast cancer. JAMA 281:1641-1642, 1999.
176. Stadtmauer EA, O'Neil A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342:1069-1076, 2000.
177. Editorial. Retraction. J Clin Oncol 2001 Jun. 1;19(11):2973
178. Farquhar C, Basser R, Marjoribanks J, et al.. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer (Cochrane Review). In: The Cochrane Library, Issue e, 2004. Chichester, UK: John Wiley & Sons, ltd.
179. Kyle RA. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy. Ann Oncol 11(Suppl 1):55-58, 2000.
180. Kolb HJ, Socie G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 131:738-744, 1999.
181. Perry MC. The chemotherapy source book. Williams and Wilkins, Baltimore, MD, 1992.
182. Sporn MB. The war on cancer. The lancet 347:1377-1381, 1996.
183. De Vita VT. The War on cancer has a birthday, and a present. J Clin Oncol 15:867-869, 1997.
184. Special Report: Measurement of Progress Against Cancer. Extramural Committee to Assess Measures of Progress Against Cancer. J Natl Cancer Inst 82:825-835, 1990.
185. Edwards, BK, Howe HL, Ries LAG, et al. Annual Report to the Nation on the status of cancer, 1973-1999, featuring implications of age and aging on U. S. cancer burden. Cancer 94:2766-2792, 2002.
186. Andersen LD, Remington P, Trentham-Dietz A, et al. Assessing a decade of progress in cancer control. The Oncologist 7:200-204, 2002.
187. Weir HK, Thun MJ, Hankey BF, et al. The Annual Report to the Nation on the Status of Cancer 1975-2000, Featuring the Use of Surveillance Data for Cancer Prevention and Control. J. Natl. Cancer Inst. 95:1276-1299, 2003.
188. Kiebert G, Wait S, Beernhard J, et al. Practice and Policy of measuring quality of life and health economics in cancer trials: A survey among co-operative trial groups. Qual Life Res. 9:1073-1080, 2000.
189. Kuenstner S, Langelotz C, Budach V, et al. The comparability of quality of life scores. a multitrait multimethod analysis of the EORTC QLQ-C30, SF-36 and FLIC questionnaires. Eur J Cancer 38:339-48, 2002.
190. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J 300:1458-1460, 1990.
191. Schipper H, Goh CR, Wang TL. Shifting the cancer paradigm: Must we kill to cure? J Clin Oncol 13:801-805, 1995.
192. Bailar JC 3rd, Smith EM. Progress against cancer? N Engl J Med. 314:1226-1232, 1986
193. Bailar JC 3rd, Gornik HL. Cancer undefeated. N Engl J Med. 336:1569-1574, 1997
194. Sporn MB. The war on cancer. The lancet 347:1377-1381, 1996.
195. Epstein, SS The Politics of Cancer Revisited. East Ridge Press, Hankins, NY, 1998.
196. Cox, Patrick: Ralph W. Yarborough, the People's Senator University of Texas Press. ISBN: 029271243X, January 2002
197. Farber S, Diamond LK, Mercer RD et al. Temporary remissions in acute leukemia in children produced by the folic acid antagonist, 4- aminopteroylglutamic acid (Aminopterin). N Engl J Med 238:787, 1948
198. Garb S. Cure for Cancer A National Goal. Springer, N. Y. 1968.
199. th, 2001, p53.
200. The Richard Nixon Library and Birthplace, http://nixonfoundation.org/ Research-Center/1971-pdf-files/1971-0026.pdf
201. http://www.nci.nih.gov/aboutnci/org.htm
202. A Plan and Budget Proposal for Fiscal Year 2005. NIH Publication No 03-5446, Oct. 2003.
203. http://cancernet.nci.nih.gov/trialsrch.shtml
204. Louis, PCA. Essays in Clinical Instruction. London, UK: P. Martin; 1834.
205. Louis PCA. Researches into the effects of blood-letting in some inflammatory diseases and on the influence of tartarized antimony and vessication in pneumonitis. Am J Med Sci 1836;18:102-111.
206. De Vita VT Jr, Serpick A. Combination chemotherapy in the treatment of advanced Hodgkin's disease (HD). Proc Am Assoc Cancer Res 8:13, 1967 (Abstract)
207. Selen M. Theory and practice of clinical trials. E-Medicine, http://www.cancer.org
208. Faguet GB, Davis HC: Regression analysis in medical research. Southern Med. J. 77:722-725, 1984.
209. Breathnach O, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19:1734-1742, 2000.
210. EORTC's "Open protocols", http://www.eortc.be
211. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998.
212. Levine M, Moutquin JM, Walton R, et al; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Can Med Assoc J 164:1681-90, 2001
213. http://bcra.nci.nih.gov/brc
214. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 352:98-101, 1998.
215. Veronesi U, Maisonneuve P, Sacchini V, et al. Tamoxifen for breast cancer among hysterectomised women. Lancet 359:1122-1124, 2002.
216. Future possibilities in the prevention of breast cancer. Breast cancer prevention trials Breast Cancer Res 2:258-263, 2000.
217. Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer, http://www.cancer.gov/clinicaltrials/view-clinicaltrials.aspx?version=p atient&cdrid=67081
218. Editorials. Peer review: reform or revolution. Br Med J 315:759-760, 1997.
219. Public library of science, http://www.publiclibraryofscience.org
220. Editorials. Measuring the social impact of research. Br Med J 323:528, 2001.
221. Eisenhofer G. Scientific productivity: Waning importance for career development of today's scientists?, http://his.com/~graeme/pandp.html
222. National Surgical Adjuvant Breast and Bowel Project, available online at http://www.nsabp. pitt.edu
223. Southwest Oncology Group, http://swog.org/visitors/WhatWedo.asp
224. Grabowski H, Vernon J. Returns to R&D on new drug introductions in the 1980s. J Health Econ 13:383-406, 1994.
225. Pharmaceutical research and manufacturers of America, http://www.phrma.org
226. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research Lancet 356:635-638, 2000.
227. Blumenthal D, Campbell EG, Anderson MS, et al. Withholding research results in academic life science: Evidence from a national survey of faculty JAMA 277:1224-1228, 1997.
228. Schulman KA, Seils DM, Timbie JW, et al. A national survey of provisions in clinical-trial agreem ents between medical schools and industry sponsors. N Engl J Med 347:1335-1341, 2002.
229. Science-Scope: Strength in numbers. Science 293:1969, 2001
230. 39 Carlsson M. Cancer patients seeking information from sources outside the health care system. Support Care Cancer 8:453-457, 2000.
231. Pentz RD, Flamm AL, Sugarman J, et al. Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. J Clin Oncol. 20:3785-91, 2002.
232. MacDonald MM, Hoffman-Goetz L. A retrospective study of the accuracy of cancer information in Ontario daily newspapers. Can J Public Health 93:142-145, 2002.
233. Medicine in the Media: The Challenge of Reporting on Medical Research Symposium. Rockville, MD, June 23-25, 2002.
234. Editorials. Have we lost are way? The Lancet 341:343-344, 1993.
235. The American Board of Internal Medicine, http://www.abim.org
236. http://www.sciencekomm.at/journals/medicine/onco.html
237. American Society of Clinical Oncology, http://www.asco.org
238. America Society of Hematology, http://www.hematology.org
239. Varmus H. Disease-specific estimates of direct and indirect costs of illness and NIH support. Bethesda, MD: Department of Health and Human Services, National Institutes of Health, Office of the Director, September 1997.
240. Johnson DH. Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience. Chest 117:133S-137S, 2000.
241. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002.
242. Cheson BD. CHOP plus Rituximab - Balancing facts and opinion.
243. Emanuel EJ, Dubler NN. Preserving the physician-patient relationship in the era of managed care. JAMA 273:323-329, 1995.
244. Council of Ethical and Judicial Affairs, American Medical Association: Ethical issues in managed care. JAMA 273:330-335, 1995.
245. Gray BH. The profit motive and patient care: The changing accountability of doctors and hospitals. Cambridge, MA Harvard University, 1991.
246. Hillman BJ, Joseph CA, Mabry MR, et al. Frequency and costs of diagnostic imaging in office practice - A comparison to self-referring and radiologist-referring physicians. New Engl J Med 327:1604-1608, 1990.
247. Kurowski B. Six key challenges in oncology disease management. Dis Manag 1:99, 1998.
248. Smyth A. Reimbursement issues for the oncologist. Oncol Reimbursement 1:1-4, 1993.
249. Smith TJ, Girtman J, Riggins J. Why academic Divisions of Hematology/Oncology are in trouble and some suggestions for resolution. J Clin Oncol 19:260-264, 2001.
250. Medical Group Management Association: Academic Practice Faculty Compensation and Production survey. 1999 Report based on 1998 Data. Medical Group Management Association. Englewood Co. 1000, pp 28-31.
251. Halbert RJ, Zaher C, Wade S, et al. Outpatient cancer drug costgs: charges, drivers, and the future. Cancer 94:1142-1150, 2002.
252. Bennett CL, Bishop MR, Tallman MS, et al. The association between physician reimbursement in the US and use of hematopoietic colony stimulation factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology. Ann Oncol 11:1355-1359, 1999.
253. Use of hematopoietic colony-stimulation factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol 9:2511-2520, 1996.
254. Ozer H. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors. Curr Opin Hematol 3:3-10, 1996.
255. Cavo M, Benni M, Ronconi S, et al. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica. 87:934-42, 2002.
256. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20
257. monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998.
258. Genentech, Rituxan sales, http://www.com/gene/ir/financials/historical/ rituxan. jsp
259. Stephenson J. Bone marrow/Stem cells: No edge in breast cancer. JAMA 281:1641-1642, 1999.
260. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342:1069-1076, 2000.
261. Faguet GB. Chronic lymphocytic leukemia: An updated review. J Clin Oncol 12:1974-1990, 1994.
262. Chronic Lymphocytic Leukemia: Advances in Molecular genetics, Biology, Diagnosis, and Management, Ed Guy B Faguet, Humana Press, Inc. Totowa, N J, 2003
263. Dighiero G. Guidelines for the clinical management of chronic lymphocytic leukemia in Chronic Lymphocytic Leukemia: Advances in Molecular genetics, Biology, Diagnosis, and Management, Ed Guy B Faguet, Humana Press, Inc. Totowa, NJ, 2003.
264. Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Gro up B 9011. J Clin Oncol. 19:3611-3621, 2001.
265. Kalil N, Cheson BD. Management of chronic lymphocytic leukemia. Drugs Aging 16:9-27, 2000.
266. Grant T. Doctor's Work: The legacy of Sir William Osler. Firefly Books. 2003.
267. http://www.schering.de/eng/irf.html?/eng/investorrelationsforum/ publications/annualreports/annualreport2001
268. Kübler-Ross E. On death and dying. Touchstone, New York, NY, 1997.
269. Jenkins V, Fallowfield L, Saul J. Information needs of patients with cancer: results from a large study in UK cancer centers. Br J Cancer 84:48-51, 2001.
270. Parker PA, Baile WF, De Moor C, et al. Breaking bad news about cancer" patients' preferences for communications. J Clin Oncol 19:2049-2056, 2001.
271. Loge JH, Kaasa S, Hytten K. Disclosing the cancer diagnosis: the patients' experiences. Eur J Cancer 33:878-882, 1997.
272. Bruera E, Neumann CM, Mazzocato C, et al. Attitudes and beliefs of palliative care physicians regarding communication s with terminally ill cancer patients. Palliat Med 14:287-298, 2000.
273. Grassi L, Giraldi T, Messina EG, et al. Physicians attitudes to and problems with truth-telling to cancer patients. Support Care Cancer 8:40-50, 2000.
274. Fallowfield LJ, Jenkins VA, Beveridge HA. Truth may hurt but deceit hurts more: communication in palliative care. Palliat Med 16:297-302, 2002.
275. Kaplowitz SA, Campo S, Chiu WT. Cancer patients' desires for communication of prognosis information. Health Commun 14:221-41, 2002.
276. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, "The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research." April 18, 1979. Department of Health and Human Services, Publication No. (OS) 780013 and No. (OS) 78-0014, Superintendent of Documents, U. S. Government Printing Office, Washington, D. C. 20402.
277. Owen E. Time Daily "Tuskegee Apology: Clinton makes amends to victims of Tuskegee study, May 16, 1997, http://www.pathfinder.com/ NwQDWgcAlAFuYgO5/time
278. Department of Energy. Advisory Committee on Human Radiation Experiments - Final Report. Superintendent of Documents U. S. Government Printing Office. Washington, D. C. 20402, June 1998, http://nattie.eh.doe.gov/systems/hrad/ report.html
279. Lalli AN. Arguments for Informed Consent Without Waivers | or Exceptions: An Analysis of Common Rule by September, 1997, http://pw2.netcom.com/~alalli/ BillSite-analysis/paper-web.html
280. Lalli AN. Letter to: Secretary Donna E. Shalala | Dept. Health and Human Services. June 06, 2000, http://pw2.netcom.com/~alalli/BillSite-analysis/ shalala-letter.html
281. Leighl N, Gattleari M, Butow P, et al. Discussing adjuvant cancer therapy. J Clin Oncol 19:1768-1778, 2001.
282. Yardley SJ, Davis CL, Sheldon F. Receiving a diagnosis of lung cancer: patients' interpretations, perceptions and perspectives. Palliat Med 15:379-86, 2001
283. Fred Hutchinson Cancer Research Center, finds violations of federal law, http://www.fda.gov/foi/warning-letters/g2083d.pdf to Dr. Dana Matthews, Dec. 31, 2001.
284. Cook-Deegan RM. Cloning human beings, http://www.bioethics.georgetown. edu/nbac/pubs/cloning2/cc8.pdf
285. Clinical research comes under scrutiny. The Lancer 2:588, 2001.
286. Nakajima K, Bidaillon D. Communication issues in the managed care environment. Forum 17:6-9, 1996.
287. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J 300:1458-1460, 1990.
288. Carlsson M. Cancer patients seeking information from sources outside the health care system. Support Care Cancer 8:453-457, 2000.
289. Cassileth BR, Zupkis RV, Sutton-Smith K, et al. Information and participation preferences among cancer patients. Ann Intern Med 92:832-836, 1980.
290. Gattellari M, Butow PN, Tattersall MH. Informed consent: what did the doctor say? Lancet. 353:1713, 1999.
291. Coulter A. Partnerships with patients: the pros and cons of shared clinical decision making. J Health Service Res Policy 2:112-121, 1997.
292. Charles C, Whelam T, Gafni A. What do we mean by partnership in making decisions about treatment? Br Med J 319:780-782, 1999.
293. Degner LF, Krsitjanson LJ, Bowman D, et al. Information needs and decisional preferences in women with breast cancer. JAMA 277:1485-1492, 1997.
294. Siminoff IA, Fetting JH, Abeloff MD. Doctor-patient communications about breast cancer adjuvant therapy. J Clin Oncol 7:1192-1200, 1989.
295. O'Connor AM, Fiset V, De Grasse C, et al. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr 25:67-80, 1999.
296. NCI's simplified informed consent, http://www.nci.nih.gov/clinical- trials/doc-header.aspx?viewid=5fca4dc 5-b6a7-4272-be96-b489f23022e5&docid= 3fccc228-0fe5-4d3a-a3b7-5eb825724da4
297. Ahmedin J, Thomas A, Murray T, et al. Facts and Figures, 2002. CA Cancer J Clin 52:23-47, 2002
298. Blackhall LJ. Must we always use CPR? N Engl J Med 317:1281-1285, 1987.
299. Paris JJ, Crone RK, Reardon F. Physicians' refusal of requested treatment. N Engl J Med 322:1012-1015, 1990.
300. Leadbetter R. Danaus. Encyclopedia Mythica, http://www.pantheon.org/ mythica.html
301. Council on Ethical and Judicial Affairs, Code of Medical Ethics, Chicago, IL: American Medical Association, 1998-1999.
302. Caplan AL. Odds and ends: trust and the debate over medical futility. Ann Intern Med 125:688-689, 1996.
303. Schneiderman LJ, Jecker NS, Jonsen AR. Medical futility: Response to critics. Ann Inter Med 125:669-674, 1996.
304. Scneiderman LJ, Jecker NS, Jonsen AR. Medical futility: its meaning and ethical implications. Ann Intern Med 112:949-954, 1990.
305. Kite S, Wilkinson S. Beyond futility: to what extent is the concept of futility useful in clinical decision-making about CPR?. Lancet Oncol 3:638-642, 2002.
306. Berry DA, Broadwater G, Klein JP, et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 20:743-750, 2002.
307. Powles TJ, Coombes RC, Smith IE, et al. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1:580-582, 1980.
308. Califano, JA Jr., Physician-Assisted Living, America, November 14, 1998, pp. 10-12.
309. Locational Information: The Routes of Santiago de Compostela in France, http://whc.unesco.org/sites/868-loc.htm
310. Saunders C. The evolution of hospices. Free inquiry. Winter 1991/92:19-23.
311. A controlled trial to improve care for seriously ill hospitalized patients. The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPPORT). The SUPPORT Principal Investigators. JAMA 1995;274:1591-1598.
312. World Health Organization. Cancer pain relief and palliative care. Geneva, Switzerland: World Health Organization; 1990:11-12.
313. Kuhn, TS. The Structure of Scientific Revolutions, University of Chicago Press, Chicago, 1962.
314. 2001 Cancer Progress Report, http://progressreport.cancer.gov
315. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Nat Cancer Institute 90:1371-1388, 1998.
316. History of tobacco, http://www.tobacco.org/History/Tobacco-History.html
317. National Vital Statistics Report, Vol 49 No. 11, October 12, 2001.
318. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA: A cancer journal for clinicians. 52:23-47, 2002.
319. Nelson DE, Kirkendall RS, Lawton RL, et al. Surveillance for smokingattributable mortality and years of potential life lost, by state - United States, 1990. Morbidity and Mortality Weekly Report 43(1):1-8, 1994.
320. Newcomb PA, Carbone PP, The health consequences of smoking: cancer. In: Fiore MC, Ed. Cigarette Smoking: A Clinical Guide to Assessment and Treatment. Philadelphia, PA: WB Saunders Co; 1992:305-331, Medical Clinics of North America.
321. Peto R, Lopez, A. D., Boreham, J., et al. Mortality from smoking in developed countries, 1950-2000: Indirect estimates from national vital statistics. New York, NY: Oxford University Press, 1994.
322. The World Health Report, 1999 Making a Difference. World Health Organization.
323. Tobacco and related Health-R&D approach. Report to R&D Committee of the Philip Morris Inc, by Dr. H. Wakeman. New York Office, November 15, 1961.
324. Ontario Task force on the primary prevention of cancer: Recommendations for the primary prevention of cancer. Toronto, Canada: Queen's printer for Ontario, 1995.
325. Knekt P, Hakama M, Jarvinen R, et al. Smoking and risk of colorectal cancer. Br J Cancer 78:136-139, 1998.
326. Wingo PA, Lynn AG, Ries MS, et al: Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 91:675-690, 1999.
327. Greelee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001 CA: A cancer journal for clinicians 51:15-27, 2001.
328. A six-month investigation by NOW with Bill Moyers, THE NATION, and the Center for Investigative Reporting, aired by PBS on April 19, 2002, http://www.pbs.org/now/indepth/041902-smuggling.html
329. Tobacco use in the US, 1990-1999, http://intouchlive.com/journals/ oncology/00007f.htm (extracted from Morbidity and Mortality Weekly Report 48:986-993, 1999.
330. Framework Convention Alliance: Building support of global tobacco control. http://fctc.org/sign-rat/signed.shtml
331. Grossman M and Chaloupka FJ. Cigarette taxes: The straw to break the camel's back. Public Health Rep 112:290-297, 1997.
332. Lung Association Report Reviews Tobacco Laws enacted in 2001, Feb. 14, 2002, http://longusa.org/press/tobacco/tobacco-021402html
333. Leigh J, Berry G, De Klerk NH, et al. Asbestos-related lung cancer: apportionment of causation and damages to asbestos and tobacco smoke. Asbestos Pathenogenesis and Litigation. G. A. Peters and B. J. Peters. Charlottesville, VA, Michie. 13: pp 141-166 (1996)
334. Blattner W. Epidemiology of HTLV-1 and associated diseases. (Blattner W, ed.). In Human retrovirology: HTLV-1. New York: Raven Press, pp 251-265 (1990)
335. Litter E, Baylis SA, Zeng Y, et al. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. Lancet 337:685-689, 1991.
336. Einstein MH, Goldberg GL. Human papillovirus and cervical neoplasia. Cancer Invest 20:1080-1085, 2002.
337. Blumberg BS, London WT. Hepatitis B virus: Pathogenesis and prevention of primary cancer of the liver. Cancer 50:2657-2665, 1982.
338. Simonetti RG, Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: A case-control study. Ann Int Med 116:97-102, 1992
339. Hausen H. Viral oncogenesis, in Microbes and malignancy. Infection as a cause of human cancer. I Parmont, Ed. New York: Oxford University Press, 1999 pp 107-130.
340. Caselmann W. Pathogenesis of hepatocellular carcinoma. Digestion 59:60-63, 1998.
341. The World Cancer Report, Ed Kleihues P, Stewart BW. Press release 3 April, 2003, http://www.who.int/mediacentre/releases/2003/pr27/en
342. Blumberg BS, Blumberg BS, Larouze B. et al. The relation of infection with hepatitis B agent to primary hepatic carcinoma. Am J Pathol 81:669-682, 1975.
343. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 328:1797-801, 1993.
344. Bosch FX, Ribes J, Borras J, et al. Epidemiology of primary liver cancer. Sem Liver Dis 19:271-285, 1999.
345. 33 Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocarcinoma and hepatic cirrhosis. Lancet 2:1004-1006, 1989.
346. Parkin M, Muir CS, Wheelan SL, et al., eds. Cancer Incidence in Five Continents, vol. VI (IARC Scientific Publication No 120). Lyon: International Agency for Research on Cancer, 1992
347. National Center for Infectious Diseases, Center for Disease Control and Prevention, http://www.cdc.gov/ncidod/diseases/hepatitis/index.htm
348. Monto A, Wright TH. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 28:441-449, 2001.
349. Jemal A, Tiwari RC, Murray T, et al. Cancer Facts & Figures 2004. CA Cancer J Clin 2004;54:8-29. http://www.cancer.org/docroot/STT/stt-0.asp
350. Yoshizama H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 62:8-17, 2001.
351. Achievements in Public Health, 1900-1999; Impact of vaccines universally recommended for children - United States, 1900-1998. MMWR, April 2, 1999; vol 48, No 12.
352. World Health. The magazine of the WHO, May 1980.
353. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336:1855-1859, 1997.
354. Schiller JT, Lowy DR: Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin Biol Ther. 1:571-581, 2001.
355. Koutsky LA, Ault KA, Wheeler CW, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645-1651, 2002.
356. Harper DM, Franco EL, Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765, 2004.
357. Malcolm Gladwell. The Picture Problem: Mammography, air power, and the limits of looking. The New Yorker, Dec. 13, 2004.
358. Smith RA, Mettlin CJ, Davis KJ, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 50:34-49, 2000.
359. Potosky AL, Kessler L, Gridley G, et al. Rise in prostatic cancer incidence associated with increased use of transurethral resection. J NCI 82:1624-1628, 1990.
360. SEER Cancer Statistics Review, 1973-1999, http://seer.cancer.gov/csr/ 1973-1999/lung.pdf
361. McNeal JE Bostwick DG, Kindrachuk RA, et al. Patterns of progression in prostate cancer. Lancet 8472, 60-63, 1986.
362. Chodak GW, Shoenberg HW. Early detection of prostate cancer by routine screening. JAMA 252:3261-3264, 1984.
363. Wajsman Z, Chu TM: Detection and diagnosis of prostate cancer. In: Murphy GP ed. Prostatic cancer. Littleton Mass. 1987, pp94-99.
364. Richert-Boe KE, Humphrey LL, Glass AG, et al. Screening digital rectal examination and prostate cancer mortality: a case-copntrol study. J Med Screening 5:99-103, 1998.
365. Thompson IM, Zeidman EJ: Presentation and clinical course of patients ultimately succumbing to carcinoma of the prostate. Scand J Urol and Nephrol. 25:111-114, 1991.
366. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al: Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. J Am Med Assoc 274:1445-1449, 1995.
367. Gann PH, Hennekens CH, Stampfer MJ, et al. A prospective evaluation of plasma PSA for detection of prostatic cancer. JAMA 273:289-294, 1995.
368. Bartsch G, Horninger W, Klocker H, et al. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria. Urology 58:417-424, 2001.
369. Crawford ED, Leewansangtong S, Goktas S, et al.: Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. The Prostate 38(4):296-302, 1999.
370. Schroder FH, Van Der Maas P, Beemsterboer P, et al.: Evaluation of the digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 90:1817-1823, 1998.
371. Breen N, Kessler L.: Changes in the use of screening mammography: evidence from 1987 and 1990 National Health Interview Surveys. Am J Pub Health 84:62-67, 1994.
372. Barton MB, Harris R, Fletcher SW: Does this patient have breast cancer? The screening clinical breast cancer examination: should it be done, ? How? JAMA 282:1270-1280, 1999.
373. Thomas DB, Gao DL, Self SG, et al. Randomized trial of breast self-examination in Shanghai: methodology and preliminary results. JNCI 89:355-365, 1997.
374. Newcomb PA, Weiss NS, Storer BE, et al. Breast self-examination in relation to the occurrence of advanced breast cancer. JNCI 83:260-265, 1991.
375. Ellman R, Moss SM, Coleman D, et al. Breast self-examination programmes in the trial of early detection of breast cancer: ten year findings. British Journal of Cancer 1993;68:208-12.
376. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2:13-Year results of randomized trial in Women aged 50-59 years. JNCI 92(18):1490-1499, 2000.
377. Rosenberg RD, Hunt WC, Williamson MR, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183, 134 screening mammograms in Albuquerque, New Mexico. Radiology 209:511-518, 1998.
378. Hakama M, Holli K, Isola J, et al.: Aggressiveness of screen-detected breast cancers Lancet 345:221-224, 1995.
379. Kerlikowske K, Grady D, Barclay J, et al. Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA 276:39-43, 1996.
380. Kerlikowske K, Grady D, Barclay J, et al. Variability and accuracy in mammographic interpretation using the American College of Radiology Breast Imaging Reporting and Data System. JNCI 90:1801-1809, 1998.
381. Elmore JG, Wells CK, Lee CH, et al. Variability in radiologists' interpretations of mammograms. NEJM 331:1493-1499, 1994.
382. Elmore JG, Wells CK, Howard DH, et al. The impact of clinical history on mammographic interpretations. JAMA 277:49-52, 1997.
383. Kerlikowske K, Grady D, Barclay J et al. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 270:2444-2450, 1993.
384. Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. NEJM 338:1089-1096, 1998.
385. Welch HG, Fisher ES: Diagnostic testing following screening mammography in the elderly. JNCI 90:1389-1392, 1998.
386. Pisano ED, Earp JA, Schell M, et al. Screening behavior of women after a false-positive mammogram. Radiol 208:245-249, 1998.
387. Gotzsche PC, Olsen O: Is screening for breast cancer with mammography justifiable? Lancet 355:129-134, 2000.
388. Statement of Andrew von Eschenbach, Director, National Cancer Institute before US Congress, February 28, 2002.
389. Tabar L, Vitak B, Chen HH, et al. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 91:1699-703, 2001.
390. Duffy SW. Tabar L, Chen HH, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 95:458-469, 2002.
391. Smith RA et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 52:8-22, 2002.
392. http://cra.nci.nih.gov/6-printer/5-future-plans.htm.
393. Initiatives for molecular target drug discovery for cancer, http://grants1.nih.gov/grants/guide/pa-files/PAR-00-060.html
394. Blower PE, Yang C, Fligner MA, et al. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J 2002;2(4):259-71
395. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 132:1497-1501, 1960.
396. Heisterkamp N, Jenster G, Ten Hoeve J. Acute leukemia in bcr/abl transgenic mice. Nature 344:251-253, 1990.
397. Daley CQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome, Science 247:824-830, 1990.
398. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcr/abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001.
399. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase myeloid leukemia. N Engl J Med 348:1048-1050, 2002.
400. Druker BJ, Talpaz, M, Resta DJ, et al. SRI571(Gleevec TM) as a paradigm for cancer therapy. Trends in Mol Med 8(suppl):14-18, 2002.
401. Von Bubnoff N, Schneller F, Peschel C, et al. Bcr-abl gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI571: a prospective study. The Lancet 359:487-491, 2002.
402. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation and amplification. Science 293:876-880, 2001.
403. Hofman WK, De Vos S, Elashoff D, et al. Relation between resistance of Philadelphia-positive acute lymphoblastic leukaemia to the tyrosine kinase inibitor STI571 and gene-expression profiles: a gene-expression study. The Lancet 359:481-486, 2002.
404. Hochhaus A, Cony-Makhoul P, Melo JV, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163, 2001.
405. Mauro MJ et al. STI571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 20:325-334, 2002.
406. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-703, 2002
407. Blanke CD, Von Mehren M, Joensuu H, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy (STI571), in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing c-KIT (CD117). Proc Am Soc Clin Onc 20:1a, 2001.
408. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409:860-921, 2001.
409. Venter JC, Adams MD, Meyers EW, et al. The sequence of the human genome, Science 291:1304-1351, 2001.
410. Drews J. Drug discovery: A historical perspective. Science 287:1960-1964, 2000.
411. Bailey D, Zanders E, Dean P. The end of the beginning for genomic medicine. Nat Biotechnol 19:207-209, 2001.
412. Foster BA, Coffey HA, Morin MJ, et al. Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510, 1999.
413. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral Onyx-015, a selective-replication adenovirus, in combination with cisplatin and 6-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6:879-885, 2000.
414. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer. 2002 Jun; 9(2):75-85
415. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. New Engl J Med 344:783-792, 2001.
416. Ewer MS, Gibbs HR, Swafford J, et al. Cardiotoxicity of patients receiving transtumumab (Herceptin): primary toxicity, synergism, sequential stress, or surveillance artifact? Semin Oncol 26:96-101, 1999.
417. Gibbs JB Mechanism-based target identification and drug discovery in cancer research. Science 287:1969-1973, 2000.
418. Workman P. Scoring the bull's-eye against cancer genome targets. Curr Opin Pharmacol 1:342-352, 2001.
419. Kipps TJ. Gene therapy in Chronic Lymphocytic Leukemia: Advances in Genetics, Biology, and Management, Ed GB Faguet, Humana Press, 2003.
420. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse B-cell lymphoma identified by gene expression profiling. Nature (Lond.) 403:503-511, 2000.
421. Hamblin, T. J., Davis, Z., Gardiner, A., et al. Unmutated Ig V (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
422. Connors T. Anticancer drugs development: The way forward. The Oncologist 1:180-181, 1996.
423. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL). I. As203 exerts dose-dependent dual effects of APL cells. Blood 89:3345-3353, 1997.
424. Adjei AA, Davis JN, Erlishman C, et al. Farnesyl transferase inhibition: use of surrogate markers. Proc Am Soc Cancer Res Plenary 9, 1999.
425. Adjei AA, Erlishman C, Davis JN, et al. A phase I trial of farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 60:1871-1877, 2000.
426. 6-benxylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 59:2402-2410, 1999.
427. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989.
428. Baidas SM, Winer EP, Fleming GF, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 18:2710-2717, 2000.
429. Simon R. New method for the design and analysis of clinical trials. Principles Practice Oncol Updates 13:1-9, 1999.
430. Kopec JA, Abrahamwicz M, Esdaile JM. Randomized discontinuation trials: Utility and efficiency. J Clin Epidemiol 46:959-971, 1993.
431. Improving Palliative Care for Cancer. Foley KM, Gelband H, editors. National Cancer Policy board - National Research Council, National Academic Press, Washington, D. C., 2001.
432. Singer PA, Martin DK, Kelner M. Quality end-of-life care: patients' perspectives. JAMA 281:163-8, 1999.
433. Teno JM, Fisher ES, Hamel MB, et al. Medical care inconsistent with patients' treatment goals: Association with 1-year Medicare resource use and survival. J Am Ger Soc 50:496-500, 2002.
434. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: Relationship to age, gender, and performance status in 1, 000 patients. Support Care Cancer 8:175-179, 2000.
435. Portenoy RK, Thaler HT, Kornblitch AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 3:183-190, 1994.
436. WHO definition of palliative care, http://www.who.int/dsa/justpub/cpl.htm
437. Burnett A, Büchner T. Risk adapted treatment of acute myeloid leukemia. Program. 7th Congress of the European Haematology Association; June 6-9, 2002; Florence, Italy.
438. Dighiero G. Clinical management: Guidelines in Chronic Lymphocytic Leukemia: Advances in Molecular genetics, Biology, Diagnosis, and Management. Ed Guy B Faguet, Humana Press, Totowa, NJ, 2003.
439. Lukes RJ, Carver LF, Hall TC, Rappaport H & Rubin T. Report of the nomenclature committee. Cancer Res 26:1311, 1966.
440. Rosenberg SA. Report of the committee on the staging of Hodgkin's disease. Cancer Res 26:1310, 1966.
441. Hreschchyshyn M, Sheehan FR & Holland JF. Visualization of retroperitoneal lymph nodes. Lymphangiography as an aid in the measurement of tumor growth. Cancer 14:205-209, 1961.
442. Enright LP, Trueblood HW & Nelsen TS. The surgical diagnosis of abdominal Hodgkin's disease. Surg Gynec Obst 130:853-858, 1970.
443. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Medico-Chirurgical Transactions 17:68-114, 1832.
444. Rosenberg SA, Kaplan H, Hoppe RT, et al. The Stanford randomized trials of the treatment of Hodgkin's disease: 1967-1980. In Rosenberg HS and Kaplan H, eds. Malignant lymphomas: etiology, immunology, pathology, treatment. Bristol-Myers cancer symposia. Vol 3. New York: Academic Press, 1982.
445. De Vita VT, Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute (NCI). Ann Intern Med 92:587-595, 1980.
446. Einhorn LH and Stephens DW. Chemotherapy of disseminated testicular cancer: a random prospective study. Cancer 46:1339-1344, 1980.
447. Krakoff IH. Systemic treatment of cancer. CA-A Cancer J Clin 46:136-141, 1996.
448. Holland JF, Frei E, Kuffe DW, Bast RC. Principles of medical oncology. Cancer Medicine e.5 Online http://www.cancer.org/eprise/main/docroot/PUB/ content/PUB-2-1-Cancer-Medicine-e5Online?
449. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid (Aminopterin). New Engl J Med 238:787-793, 1948.
450. The National Cancer Program: Assessing the past, charting the future, 1999 Annual Report. http:\\deainfo.nci.nih.gov/ADVISORY/pcp/pcp99rpt/99report. htm